Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis
Qian Yang, Waseem Hassan, Hammad Ahmed, Haiyan Zheng · 2026
Read Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis by Qian Yang, Waseem Hassan, Hammad Ahmed, Haiyan Zheng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13591686.txt.
Description
Qian Yang and three colleagues pool, in 2026, studies on whether a popular class of diabetes drugs speeds eye damage. Diabetic retinopathy, harm to the retina from high blood sugar, is a leading cause of vision loss. GLP-1 drugs lower sugar and weight, yet some trials hinted at faster eye decline. From 161 records, 11 studies qualified, covering trials and record based work across three continents.
Taken together, the drugs showed no firm link to worsening eye disease. Results split by drug, though: semaglutide carried the highest risk figures in two studies, well above the pooled trend. Checks for hidden bias came back clean. Yang and the team urge targeted study of semaglutide and eye outcomes before the worry is settled.
Catalog record
| CREATOR | Qian Yang, Waseem Hassan, Hammad Ahmed, Haiyan Zheng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57110 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |